Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.78 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.71 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5698670 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL4617859 | 0.88 | PTGS2 (0.83) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL15346938 | 0.88 | PTGS2 (0.83) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL15347199 | 0.87 | PTGS2 (1.00) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL15346891 | 0.87 | PTGS2 (0.91) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL19664982 | 0.87 | PTGS2 (0.98) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL15346898 | 0.87 | PTGS2 (1.00) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL15346857 | 0.87 | PTGS2 (0.81) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL15346838 | 0.87 | PTGS2 (0.81) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL8953880 | 0.86 | PTGS2 (0.81) | PTGS2PTGS1PDPK1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6403629-B2 | 1-(P-(METHYLSULFONAMIDO)PHENYL)-3-TRIFLUOROMETHYL-5-PHENYLPYRA ZOLONE AND DERIVATIVES; ANTIINFLAMMATORY AGENTS | J.B. CHEMICAL AND PHARMACEUTICALS LIMITED (IN) | 2002-06-11 | — | — | US | claimed |
| US-20010047023-A1 | New Heterocyclic compounds for therapeutic use | J.B. CHEMICALS & PHARMACEUTICALS LIMITED | 2001-11-29 | — | — | US | claimed |
| US-6403629-B2 | 1-(P-(METHYLSULFONAMIDO)PHENYL)-3-TRIFLUOROMETHYL-5-PHENYLPYRA ZOLONE AND DERIVATIVES; ANTIINFLAMMATORY AGENTS | J.B. CHEMICAL AND PHARMACEUTICALS LIMITED (IN) | 2002-06-11 | — | — | US | disclosed |
| US-20010047023-A1 | New Heterocyclic compounds for therapeutic use | J.B. CHEMICALS & PHARMACEUTICALS LIMITED | 2001-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047023-A1 | New Heterocyclic compounds for therapeutic use | AADAC, NAT1, FPR1 | PTGS2 352/4885PTGS1 94/4885PDPK1 4170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.